KALV
$18.53
Kalvista Pharmaceuticals
$.10
.54%
KALV
Earnings Whisper ®
N/A
2nd Quarter October 2020
Consensus:  ($0.70)
Revenue:  $2.50 Mil
Tuesday
Dec 15
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when KALV reports earnings?
Beat
Meet
Miss

Where is KALV's stock price going from here?
Up
Flat
Down
Stock chart of KALV
Analysts
Summary of analysts' recommendations for KALV
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States.